Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Extemporaneous Aprepitant Oral Suspension
NCT03245918Phase 1Completed
- Sponsor
- SickKids
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by SickKids. Primary endpoint: Relative Bioavailability of the oral suspension relative to the capsule at 6 weeks. Started Aug 2017; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03245918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245918.